Dvorit Samid
Profile
Dvorit Samid worked as Vice President-Medical Affairs at Synta Pharmaceuticals Corp.
and as Senior Vice President-Medical Affairs at NantKwest, Inc. She holds a doctorate degree from The Catholic University of America and an undergraduate degree from The Hebrew University of Jerusalem.
Former positions of Dvorit Samid
Companies | Position | End |
---|---|---|
IMMUNITYBIO, INC. | Chief Tech/Sci/R&D Officer | - |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | - |
Training of Dvorit Samid
The Catholic University of America | Doctorate Degree |
The Hebrew University of Jerusalem | Undergraduate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
NantKwest, Inc.
NantKwest, Inc. BiotechnologyHealth Technology NantKwest, Inc. engages in the research and development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Dvorit Samid